Seminars in Cancer Biology

Article	Citations
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	384
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	329
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	263
The role of transcription factors in the acquisition of the four latest proposed hallmarks of cancer and corresponding enabling characteristics	243
Extracellular vesicles proteins for early cancer diagnosis: From omics to biomarkers	220
Recent advances in microbial toxin-related strategies to combat cancer	215
Alternative splicing in EMT and TGF-β signaling during cancer progression	193
New opportunities and challenges of venom-based and bacteria-derived molecules for anticancer targeted therapy	183
Extracellular matrix proteins in metastases to the liver – Composition, function and potential applications	178
Microbiome dysbiosis in cancer: Exploring therapeutic strategies to counter the disease	173
Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies	169
Comparative analysis of the minimal information for studies of extracellular vesicles guidelines: Advancements and implications for extracellular vesicle research	164
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?	162
PROTAC as a novel anti-cancer strategy by targeting aging-related signaling	162
Precision medicine in myeloid malignancies	161
Small secretory proteins of immune cells can modulate gynecological cancers	160
Chemokines network in bone metastasis: Vital regulators of seeding and soiling	155
Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators	152
Possible connection between diet and microRNA in cancer scenario	149
Role of non-coding RNAs in the progression and resistance of cutaneous malignancies and autoimmune diseases	146
Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development	145
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy	138
Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesis	135
The HECT family of E3 ubiquitin ligases and PTEN	133
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	128

A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma	126
Sex dimorphism in the tumor microenvironment – From bench to bedside and back	126
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	126
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	122
Combining radiation therapy with immune checkpoint blockade for the treatment of small cell lung cancer	120
Editorial Board	116
Editorial Board	113
Editorial Board	111
Aberrant transcription factors in the cancers of the pancreas	107
Editorial Board	107
Twenty-third Heidelberger Symposium on cancer research	106
Editorial Board	105
Editorial Board	104
Editorial Board	102
Editorial Board	102
Brain macrophage senescence in glioma	101
Editorial Board	101
Advances in biology and novel treatments of SCLC	101
Stem-loop binding protein and metal carcinogenesis	100
Dietary molecules and experimental evidence of epigenetic influence in cancer chemoprevention: An insight	100
Tumor-derived nanoseeds condition the soil for metastatic organotropism	100
The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update	98
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	98
Deregulated transcription factors in the emerging cancer hallmarks	98
99mTC-sestamibi breast imaging: Current status, new ideas and future perspectives	94
What we know on the potential use of exosomes for nanodelivery	94
Biology of cancer: Understanding the supracellular control of mitosis in physiological processes and malignancy	93
Precision diagnostics in lymphomas – Recent developments and future directions	92
Transcriptional factors targeting in cancer stem cells for tumor modulation	92
Harmonization after the GDPR? Divergences in the rules for genetic and health data sharing in four member states and ways to overcome them by EU measures: Insights from Germany, Greece, Latvia and Swe	91
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	90
Understanding and targeting prostate cancer cell heterogeneity and plasticity	90
Obesity and multiple myeloma: Emerging mechanisms and perspectives	90
HDL and cancer - causality still needs to be confirmed? Update 2020	88
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	86
Therapy-induced shaping of the glioblastoma microenvironment: Macrophages at play	86
Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer	86
Critical DNA damaging pathways in tumorigenesis	86
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	85
Nanomedicine for urologic cancers: diagnosis and management	84
Apolipoprotein mimetics in cancer	83
Arsenic-induced epigenetic changes in cancer development	82
Deep computational pathology in breast cancer	82
Understanding the cross-talk between human microbiota and gastrointestinal cancer for developing potential diagnostic and prognostic biomarkers	81
Dysregulations of long non-coding RNAs − The emerging “lnc” in environmental carcinogenesis	80
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	80
Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets	80
Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer	80
Extracellular vesicles in cancer pros and cons: The importance of the evidence-based medicine	79
Immune evasion on the nanoscale: Small extracellular vesicles in pancreatic ductal adenocarcinoma immunity	78

Profiling of extracellular vesicles in oral cancer, from transcriptomics to proteomics	78
Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies	77
Targeting intratumoral hypoxia to enhance anti-tumor immunity	76
Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma	75
cGAS/STING signalling pathway in senescence and oncogenesis	74
Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges	74
Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes	71
The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer	70
Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology	70
Polyploid giant cancer cells: An emerging new field of cancer biology	69
An updated overview on metal nanoparticles toxicity	68
Role of endolysosome function in iron metabolism and brain carcinogenesis	67
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	67
Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy	66
DNMT1: A key drug target in triple-negative breast cancer	65
RNA-binding proteins: Underestimated contributors in tumorigenesis	64
Curcumin: A therapeutic strategy for colorectal cancer?	63
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	62
Gut microbiota and immunosenescence in cancer	62
Inside the stemness engine: Mechanistic links between deregulated transcription factors and stemness in cancer	62
The Relationship of the Microbiome, Associated Metabolites and the Gut Barrier with Pancreatic Cancer	61
Dietary fat, bile acid metabolism and colorectal cancer	60
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	60
Liver regeneration and liver metastasis	60
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis	60
Multifaceted role of chemokines in solid tumors: From biology to therapy	59
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting	59
Breast cancer metastasis to bone: From epithelial to mesenchymal transition to breast osteoblast-like cells	59
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	59
RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer	58
Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism	58
Checkpoint: Inspecting the barriers in glioblastoma immunotherapies	58
Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers	57
The Warburg effect: the hacked mitochondrial-nuclear communication in cancer	57
Role of iron in cancer	57
RNA-binding proteins and cancer metastasis	57
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	57
The intricate nature of senescence in development and cell plasticity	57
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	56
Historical perspective of tumor glycolysis: A century with Otto Warburg	56
Emerging applications of bacteria as antitumor agents	54
Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis	54
Artificial intelligence aids in development of nanomedicines for cancer management	54
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	53
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	53
Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction	53
Extracellular vesicles in cancer progression	52
Precision cancer medicine: What has translated into clinical use in Belgium?	51
Small cell lung cancer: Subtypes and therapeutic implications	51
Aberrant protein synthesis and cancer development: The role of canonical eukaryotic initiation, elongation and termination factors in tumorigenesis	51
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer	51
The evolutionary legacy of immune checkpoint inhibitors	51
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	51
Nutrition and upper gastrointestinal cancers: An overview of current understandings	50
Gut microbes in gastrointestinal cancers	50
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	50
T-cell-based breast cancer immunotherapy	50
Green nanoparticles as multifunctional nanomedicines: Insights into anti-inflammatory effects, growth signaling and apoptosis mechanism in cancer	50
Innovative trial design in precision oncology	50
Precision medicine in pediatric solid cancers	50
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	49
Nano-targeting vascular remodeling in cancer: Recent developments and future directions	49
Multifaceted effects of obesity on cancer immunotherapies: Bridging preclinical models and clinical data	49
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era	48
Nanomedicines: Targeting inflammatory pathway in cancer and aging	48
Special issue: Therapy-induced remodeling of the tumor microenvironment	48
Editorial Board	48
Editorial Board	48
Editorial Board	48
Editorial Board	48
CDK inhibitors from past to present: A new wave of cancer therapy	48
Editorial Board	48
Editorial Board	48
Editorial Board	48
Editorial Board	47
The role of autophagy in metal-induced urogenital carcinogenesis	47
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	47
Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints	47
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	47
Special issue Microbes in Cancer Research in 'Seminar in Cancer Biology' 2021	47

Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	47
Genetics and Genomics of Breast Cancer: update and translational perspectives	46
Editorial: Role of chemokines in tumor heterogeneity	46
Diverse roles of EV-RNA in cancer progression	46
Can medical imaging identify the histopathological growth patterns of liver metastases?	46
One label is all you need: Interpretable AI-enhanced histopathology for oncology	46
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	46
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy	46
Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy	46
Emerging role of microbiota in immunomodulation and cancer immunotherapy	46
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	46
Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities	45
Clinical application of AI-based PET images in oncological patients	45
The second half of mitosis and its implications in cancer biology	45
Artificial intelligence in oncology: From bench to clinic	45
Epigenetic remodelling under hypoxia	44
Immune senescence: A key player in cancer biology	44
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	44
Therapy-induced polyploidization and senescence: Coincidence or interconnection?	43
Regulatory effects of noncoding RNAs on the interplay of oxidative stress and autophagy in cancer malignancy and therapy	43
PIWI-interacting RNAs in human cancer	43
Genomic profiling of sporadic liver metastatic colorectal cancer	43
Immune-modulating and anti-inflammatory marine compounds against cancer	43
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	43
Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications	43
Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy	43
The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community	42
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	42
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	41
Predicting liver metastases growth patterns: Current status and future possibilities	41
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	41
miRNAs mediated drug resistance in hematological malignancies	41
Polyploidy formation in cancer cells: How a Trojan horse is born	41
Anticancer properties of chimeric HDAC and kinase inhibitors	41
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	40
Ferroptosis and immunosenescence in colorectal cancer	40
Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers	40
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	40
Origins and molecular effects of hypoxia in cancer	39
Non-coding RNAs and lipids mediate the function of extracellular vesicles in cancer cross-talk	39
Editorial Board	39
p62 functions as a signal hub in metal carcinogenesis	38
Optimal timing of PD-1 blockade in combination with oncolytic virus therapy	38
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	38
Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives	38
Predictive biomarkers for response to immune checkpoint inhibition	38
The IL-1 family in tumorigenesis and antitumor immunity	38
Emerging role of artificial intelligence in diagnosis, classification and clinical management of glioma	38
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	37
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging	37
Obesity and immune-checkpoint inhibitors in advanced melanoma: A meta-analysis of survival outcomes from clinical studies	37
The emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer	37
Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective	37
Chemokines in colon cancer progression	37
Transcriptional regulation of EMT transcription factors in cancer	37
Immune cellular components and signaling pathways in the tumor microenvironment	37
The altered lipidome of hepatocellular carcinoma	37
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	37
Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors	37
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	37
Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview	37
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	36
Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics	36
Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities	36
Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation	36
Hypoxia signaling and metastatic progression	36
Cancer extracellular vesicles, tumoroid models, and tumor microenvironment	36
Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	36
From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction	36
Small cell lung cancer: Novel treatments beyond immunotherapy	35
miRNA dysregulation is an emerging modulator of genomic instability	35
Giant cells: Linking McClintock’s heredity to early embryogenesis and tumor origin throughout millennia of evolution on Earth	35
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	35
Notch signaling in cancer: Complexity and challenges on the path to clinical translation	35
Hedgehog signaling mechanism and role in cancer	34
Post-transcriptional diversity in riboproteins and RNAs in aging and cancer	34
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	34
Nanoparticles: Attractive tools to treat colorectal cancer	34
Pathology of triple negative breast cancer	34
Cell cycle stress in normal human cells: A route to “first cells” (with/without fitness gain) and cancer-like cell-shape changes	34
Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance	33
Artificial intelligence-aided optical imaging for cancer theranostics	33
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	33
Cucurbitacin mediated regulation of deregulated oncogenic signaling cascades and non-coding RNAs in different cancers: Spotlight on JAK/STAT, Wnt/β-catenin, mTOR, TRAIL-mediated pathways	33
Microbiota and gastric cancer	33
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	33
New Advances in Molecular Breast Cancer Pathology	33
Effects of caloric restriction on immunosurveillance, microbiota and cancer cell phenotype: Possible implications for cancer treatment	33
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	33
Germline genetic variability in pancreatic cancer risk and prognosis	32
Precision medicine in cancer: A paradigm shift	32
Targeting tumor micro-environmental pathways for cancer therapy	32
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	32
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities	32
Editorial Board	32